Frank P Vleggaar

List of Publications by Year
in descending order

77 papers	5,160 citations	109137 35 h-index	85405 71 g-index
79 all docs	79 docs citations	79 times ranked	8302 citing authors

#	Article	IF	Citations
1	TGF-Î² promotes microtube formation in glioblastoma through thrombospondin 1. Neuro-Oncology, 2022, 24, 541-553.	0.6	38
2	Physics of Brain Cancer: Multiscale Alterations of Glioblastoma Cells under Extracellular Matrix Stiffening. Pharmaceutics, 2022, 14, 1031.	2.0	16
3	The Unfolded Protein Response Sensor PERK Mediates Stiffness-Dependent Adaptation in Glioblastoma Cells. International Journal of Molecular Sciences, 2022, 23, 6520.	1.8	4
4	CD146 increases stemness and aggressiveness in glioblastoma and activates YAP signaling. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	9
5	Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma. Journal of Neuro-Oncology, 2021, 153, 211-222.	1.4	7
6	A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker. Lung Cancer, 2021, 154, 13-22.	0.9	7
7	Understanding Lung Carcinogenesis from a Morphostatic Perspective: Prevention and Therapeutic Potential of Phytochemicals for Targeting Cancer Stem Cells. International Journal of Molecular Sciences, 2021, 22, 5697.	1.8	12
8	Necrosis binding of Ac-Lys0(IRDye800CW)-Tyr3-octreotate: a consequence from cyanine-labeling of small molecules. EJNMMI Research, 2021, 11, 47.	1.1	5
9	The unfolded protein response as regulator of cancer stemness and differentiation: Mechanisms and implications for cancer therapy. Biochemical Pharmacology, 2021, 192, 114737.	2.0	21
10	Three-dimensionalÂculture models to study glioblastoma â€" current trends and future perspectives. Current Opinion in Pharmacology, 2021, 61, 91-97.	1.7	11
11	SK channel activation potentiates auranofin-induced cell death in glio- and neuroblastoma cells. Biochemical Pharmacology, 2020, 171, 113714.	2.0	16
12	Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy. Frontiers in Immunology, 2019, 10, 1530.	2.2	51
13	ER stress and UPR activation in glioblastoma: identification of a noncanonical PERK mechanism regulating GBM stem cells through SOX2 modulation. Cell Death and Disease, 2019, 10, 690.	2.7	51
14	STEM-11. CD146/MCAM REGULATES MESENCHYMAL PROPERTIES, STEMNESS, RADIO-RESISTANCE AND YAP ACTIVITY IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi236-vi236.	0.6	0
15	Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting. Biochemical Pharmacology, 2019, 160, 121-133.	2.0	99
16	Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. Cell Reports, 2018, 22, 3206-3216.	2.9	19
17	Circulating miRNAs in patients with Barrettâ€™s esophagus, high-grade dysplasia and esophageal adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 1150-1156.	0.6	11
18	IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma. Oncotarget, 2018, 9, 15721-15731.	0.8	28

#	Article	IF	Citations
19	MBRS-36. IDENTIFICATION OF TWO PROTEIN-SIGNALING STATES DELINEATING TRANSCRIPTIONALLY HETEROGENEOUS HUMAN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i136-i136.	0.6	0
20	MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines. Npj Breast Cancer, 2018, 4, 20.	2.3	52
21	EMTâ€•and METâ€•related processes in nonepithelial tumors: importance for disease progression, prognosis, and therapeutic opportunities. Molecular Oncology, 2017, 11, 860-877.	2.1	121
22	MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelialâ€“mesenchymal transition, decreased ERÎ± expression and AKT activation. Cancer Letters, 2017, 386, 65-76.	3.2	54
23	Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses. Journal of Neuro-Oncology, 2017, 131, 11-20.	1.4	14
24	The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma. Biochemical Pharmacology, 2016, 118, 1-8.	2.0	105
25	Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 535-542.	1.1	38
26	BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity. Toxicology and Applied Pharmacology, 2016, 295, 56-67.	1.3	13
27	Serum-Induced Differentiation of Glioblastoma Neurospheres Leads to Enhanced Migration/Invasion Capacity That Is Associated with Increased MMP9. PLoS ONE, 2015, 10, e0145393.	1.1	35
28	GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma. Digestive and Liver Disease, 2015, 47, 73-80.	0.4	13
29	Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1Î±â€“ZEB1 axis. Cancer Letters, 2015, 359, 107-116.	3.2	251
30	CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. Radiotherapy and Oncology, 2015, 117, 152-158.	0.3	19
31	TGF-Î² Antibody Uptake in Recurrent High-Grade Glioma Imaged with ⁸⁹Zr-Fresolimumab PET. Journal of Nuclear Medicine, 2015, 56, 1310-1314.	2.8	78
32	Two death-inducing human TRAIL receptors to target in cancer: Similar or distinct regulation and function?. Biochemical Pharmacology, 2014, 91, 447-456.	2.0	53
33	The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells. Cancer Chemotherapy and Pharmacology, 2014, 73, 1273-1283.	1.1	12
34	Loss of CD44 and SOX2 Expression is Correlated with a Poor Prognosis in Esophageal Adenocarcinoma Patients. Annals of Surgical Oncology, 2014, 21, 657-664.	0.7	30
35	The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma. SpringerPlus, 2014, 3, 495.	1.2	14
36	Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach. PLoS ONE, 2014, 9, e115687.	1.1	24

#	Article	IF	Citations
37	Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?. Critical Reviews in Oncology/Hematology, 2013, 85, 363-372.	2.0	61
38	MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 851-860.	2.2	37
39	TGF-Î² as a therapeutic target in high grade gliomas â€“ Promises and challenges. Biochemical Pharmacology, 2013, 85, 478-485.	2.0	133
40	Targeting <scp>FLIP</scp> and Mclâ€•1 using a combination of aspirin andÂsorafenib sensitizes colon cancer cells to <scp>TRAIL</scp>. Journal of Pathology, 2013, 229, 410-421.	2.1	28
41	Targeting apoptosis pathways in lung cancer. Cancer Letters, 2013, 332, 359-368.	3.2	79
42	Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3 dependent invasion in resistant non-small cell lung cancer cells. Journal of Cell Science, 2012, 125, 4651-61.	1.2	57
43	Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochemical Pharmacology, 2012, 83, 207-217.	2.0	68
44	Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 123-140.	3.3	96
45	Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy. Biochemical Pharmacology, 2010, 80, 423-430.	2.0	78
46	Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. Cancer Science, 2010, 101, 440-447.	1.7	27
47	Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointestinal Endoscopy, 2010, 71, 490-499.	0.5	471
48	Comparative proteomics analysis of caspase-9-protein complexes in untreated and cytochrome c/dATP stimulated lysates of NSCLC cells. Journal of Proteomics, 2009, 72, 575-585.	1.2	23
49	Genotype analysis of the VNTR polymorphism in the <i>SMYD3</i> histone methyltransferase gene: Lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC. International Journal of Cancer, 2008, 122, 1441-1442.	2.3	7
50	TRAIL and cancer therapy. Cancer Letters, 2008, 263, 14-25.	3.2	153
51	Global Histone Modifications Predict Prognosis of Resected Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 4358-4364.	0.8	257
52	Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the nonâ€“small cell lung cancer cell line NCI-H460. Molecular Cancer Therapeutics, 2007, 6, 1046-1053.	1.9	47
53	TRAIL therapy in nonâ€“small cell lung cancer cells: sensitization to death receptorâ€“mediated apoptosis by proteasome inhibitor bortezomib. Molecular Cancer Therapeutics, 2007, 6, 2103-2112.	1.9	111
54	Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics - Clinical Applications, 2007, 1, 598-604.	0.8	31

#	Article	IF	Citations
55	Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: A small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. Experimental Cell Research, 2007, 313, 1215-1224.	1.2	44
56	Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Human Pathology, 2006, 37, 78-86.	1.1	63
57	A real-time RT-PCR assay for the quantitiative determination of adenoviral gene expression in tumor cells. Journal of Virological Methods, 2006, 133, 53-61.	1.0	6
58	TUCAN/CARDINAL/CARD8 and apoptosis resistance in non-small cell lung cancer cells. BMC Cancer, 2006, 6, 166.	1.1	11
59	Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. International Journal of Cancer, 2006, 118, 209-214.	2.3	142
60	FANCD2 Expression in Advanced Nonâ€“Small-Cell Lung Cancer and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer, 2005, 6, 250-254.	1.1	16
61	Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export. Human Molecular Genetics, 2005, 14, 1271-1281.	1.4	30
62	Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling. Molecular Pharmacology, 2005, 68, 502-510.	1.0	107
63	Cell Death Independent of Caspases: A Review. Clinical Cancer Research, 2005, 11, 3155-3162.	3.2	792
64	Cathepsin B Mediates Caspase-Independent Cell Death Induced by Microtubule Stabilizing Agents in Non-Small Cell Lung Cancer Cells. Cancer Research, 2004, 64, 27-30.	0.4	204
65	Conditionally Replicating Adenoviruses Kill Tumor Cells via a Basic Apoptotic Machinery-Independent Mechanism That Resembles Necrosis-Like Programmed Cell Death. Journal of Virology, 2004, 78, 12243-12251.	1.5	81
66	Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. Cancer Gene Therapy, 2004, 11, 539-546.	2.2	33
67	Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. Experimental Cell Research, 2004, 298, 535-548.	1.2	37
68	Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner. Experimental Cell Research, 2003, 286, 381-395.	1.2	18
69	Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins. Biochemical Journal, 2003, 373, 251-259.	1.7	16
70	Toward a New Generation of Conditionally Replicating Adenoviruses: Pairing Tumor Selectivity with Maximal Oncolysis. Human Gene Therapy, 2002, 13, 485-495.	1.4	91
71	CRM1-Mediated Nuclear Export Determines the Cytoplasmic Localization of the Antiapoptotic Protein Survivin. Experimental Cell Research, 2002, 275, 44-53.	1.2	139
72	Cloning and Analysis of the Mouse Fanconi Anemia Group A cDNA and an Overlapping Penta Zinc Finger cDNA. Genomics, 2000, 67, 273-283.	1.3	15

#	Article	IF	Citations
73	Do Fanconi anemia genes control cell response to cross-linking agents by modulating cytochrome P-450 reductase activity?. Drug Resistance Updates, 2000, 3, 211-215.	6.5	9
74	Resistance to Mitomycin C Requires Direct Interaction between the Fanconi Anemia Proteins FANCA and FANCG in the Nucleus through an Arginine-rich Domain. Journal of Biological Chemistry, 1999, 274, 34212-34218.	1.6	51
75	Normal expression of the Fanconi anemia proteins FAA and FAC and sensitivity to mitomycin C in two Patients with Seckel syndrome. , 1999, 83, 388-391.		14
76	Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C. Blood, 1999, 93, 363-369.	0.6	0
77	Abnormal Microsomal Detoxification Implicated in Fanconi Anemia Group C by Interaction of the FAC Protein With NADPH Cytochrome P450 Reductase. Blood, 1998, 92, 3050-3056.	0.6	145